萬潤股份(002643.SZ):“年產65噸光刻膠樹脂系列產品項目”已經達到預定可使用狀態,並已有產出產品通過下游客户驗證
格隆匯8月22日丨萬潤股份(002643.SZ)於2023年8月21日15:00~16:00接受特定對象調研,就“公司半導體制造材料有何新的進展?”,公司回覆稱,在項目方面,公司“年產65噸光刻膠樹脂系列產品項目”已經達到預定可使用狀態,並已有產出產品通過下游客户驗證,後續可根據客户訂單情況生產供應。
公司目前在半導體制造材料領域的相關產品主要包括光刻膠單體、光刻膠樹脂、光致產酸劑以及半導體制程中清洗劑添加材料等,下游市場開發工作持續推進中,目標是成為全球半導體制造材料產業的堅實後盾,為國內外半導體制造材料產業發展提供產品與技術支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.